Camostat mesylate
Based on 46 publication(s) in Google Scholar
Camostat mesylate (Camostat mesilate) is an orally active, synthetic serine protease inhibitor for chronic pancreatitis. Camostat mesylate, an inhibitor of TMPRSS2, shows antiviral activity against SARS-CoV-2. Camostat mesylate also inhibits the activity of prostasin, trypsin, and matriptase.
For research use only. We do not sell to patients.
- Purity: 99.94%
- CAS No.: 59721-29-8
- Formula: C21H26N4O8S
- Molecular Weight:494.52
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
FDA-Approved Drug Library
HY-L022
-
Antiviral Compound Library
HY-L027
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Off-patent Drug Library
HY-L141
-
Protease Inhibitor Library
HY-L147
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Camostat mesylate
More- Signal Transduct Target Ther. 2022 Mar 11;7(1):83. [Abstract]
- Nature. 2022 Mar;603(7902):693-699. [Abstract]
- Cell. 2023 Feb 16;186(4):850-863.e16. [Abstract]
- Nat Microbiol. 2025 Nov;10(11):2860-2874. [Abstract]
- Nat Microbiol. 2024 Sep;9(9):2383-2394. [Abstract]
- Nat Commun. 2025 Dec 11;16(1):11002. [Abstract]
- Nat Commun. 2025 Jul 7;16(1):6241. [Abstract]
- Nat Commun. 2024 Oct 9;15(1):8728. [Abstract]
- Nat Commun. 2024 Jul 3;15(1):5606. [Abstract]
- Nat Commun. 2022 Jul 26;13(1):4331. [Abstract]
- Nat Commun. 2022 Mar 17;13(1):1444. [Abstract]
- Nat Chem Biol. 2022 Sep;18(9):963-971. [Abstract]
- Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121. [Abstract]
- Sci Adv. 2023 Jan 20;9(3):eadd3867. [Abstract]
- Cell Discov. 2021 Dec 14;7(1):119. [Abstract]
- EBioMedicine. 2023 Sep:95:104753. [Abstract]
- Cell Rep Med. 2022 Sep 20;3(9):100743. [Abstract]
- Sci China Life Sci. 2025 Oct 24. [Abstract]
- Proc Natl Acad Sci U S A. 2022 Jan 25;119(4):e2117576119. [Abstract]
- Emerg Microbes Infect. 2022 Dec;11(1):2275-2287. [Abstract]
- Sci Signal. 2024 Aug 20;17(850):eadn3785. [Abstract]
- Eur J Med Chem. 2021 Nov 15:224:113683. [Abstract]
- Cell Prolif. 2025 May 15:e70060. [Abstract]
- Biochem Pharmacol. 2023 Jul:213:115617. [Abstract]
- Virulence. 2026 Dec;17(1):2691344. [Abstract]
- PLoS Pathog. 2025 Oct 14;21(10):e1013593. [Abstract]
- Eur J Pharmacol. 2023 Jan 5:938:175394. [Abstract]
- mBio. 2022 Dec 20;13(6):e0256622. [Abstract]
- Eur J Pharmacol. 2022 Mar 15:919:174795. [Abstract]
- Antiviral Res. 2023 Jun:214:105606. [Abstract]
- J Virol. 2026 Apr 21;100(4):e0027026. [Abstract]
- J Virol. 2025 Nov 18:e0127425. [Abstract]
- J Virol. 2025 Aug 11:e0105525. [Abstract]
- J Virol. 2023 May 31;97(5):e0032423. [Abstract]
- Viruses. 2022 Feb 8;14(2):353. [Abstract]
- Am J Physiol Renal Physiol. 2024 Aug 1;327(2):F265-F276. [Abstract]
- Biosaf Health. 2022 Feb;4(1):38-44. [Abstract]
- bioRxiv. 2026 May 7.
- Res Sq. 2024 Nov 21:rs.3.rs-5454588. [Abstract]
- SSRN. 2024 Jul 11.
- SSRN. 2024 Jan 26.
- Res Sq. 2023 Sep 11:rs.3.rs-3220157. [Abstract]
- Utrecht University. 2022 Jul.
- Research Square Preprint. 2022 Jan.
- Universidade de São Paulo. 2020 Sep.
- SSRN. 2020 Jun.
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
WB
-
Bio/Physico-chemical Assay
-
RT-PCR
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Caco-2 | CC50 |
>20 μM
Compound: CAMOSTAT
|
Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay
Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay
|
10.21203/rs.3.rs-23951/v1 |
| Caco-2 | IC50 |
0.64 μM
Compound: CAMOSTAT
|
Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging
Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging
|
10.21203/rs.3.rs-23951/v1 |
Camostat mesylate (Camostat mesilate) inhibits both monocyte chemoattractant protein-1 (MCP-1) and TNF-α production from monocytes, and proliferation and MCP-1 production from PSCs[1].
Camostat mesylate, a trypsin-like protease inhibitor, provides a potent (IC50=50 nM) and prolongs attenuation of ENaC function in human airway epithelial cell models that is reversible upon the addition of excess trypsin[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6-8 week old female BALB/c mice (lethal SARS-CoV infection model)[4]
-
Dosage:30 mg/kg
-
Administration:P.o.; twice a day for 9 days
-
Result:Effective in protecting mice against death due to a lethal infection by SARS-CoV, with a survival rate of ∼60%.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 59721-29-8
-
Appearance Solid
-
Molecular Weight 494.52
-
Formula C21H26N4O8S
-
Color White to off-white
-
SMILES
O=C(OCC(N(C)C)=O)CC1=CC=C(OC(C2=CC=C(NC(N)=N)C=C2)=O)C=C1.CS(=O)(O)=O
-
Synonyms
Camostat mesilate; FOY305; FOY-S980
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)
Publications (46)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
2022 Mar 11;7(1):83. PMID: 35277473
Camostat mesylate purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2022 Mar 11;7(1):83. [Abstract]
Camostat mesylate (2-20 μM; 1 h) inhibited SARS-CoV-2 infection of Caco2 cells in a dose-dependent manner.
-
Nature
2022 Mar;603(7902):693-699. PMID: 35062016
Camostat mesylate purchased from MedChemExpress. Usage Cited in: Nature. 2022 Mar;603(7902):693-699. [Abstract]
VeroE6-TMPRSS2 cells were pretreated with Camostat mesylate (1–50 μM; 2 h) followed by transduction with pseudoviruses carrying the spike protein of SARS-CoV-2 WT, Alpha, Beta, Delta, or Omicron. Pseudovirus entry was quantified by measuring the luciferase signal of the cell lysates at 24 h.p.i.
Camostat mesylate purchased from MedChemExpress. Usage Cited in: Nature. 2022 Mar;603(7902):693-699. [Abstract]
VeroE6-TMPRSS2 cells were pretreated with Camostat mesylate (1-50 μM; 2 h) and challenged with the indicated authentic SARS-CoV-2 variants at 0.1 m.o.i.. The amount of viral subgenomic envelope RNA in the collected cell lysates at 24 h.p.i. was determined using RT–qPCR.
-
Cell
A bat MERS-like coronavirus circulates in pangolins and utilizes human DPP4 and host proteases for cell entry. [Abstract]2023 Feb 16;186(4):850-863.e16. PMID: 36803605 -
Nat Microbiol
2025 Nov;10(11):2860-2874. PMID: 41168429
Camostat mesylate purchased from MedChemExpress. Usage Cited in: Nat Microbiol. 2025 Nov;10(11):2860-2874. [Abstract]
TMPRSS2 inhibitor Camostat mesylate (66.7 μM; 1 h; 37 ℃) dose-dependently inhibited pseudovirus entry of HKU25 clade or HKU5-1 in Caco-2 cells overexpressing the indicated ACE2s.
-
Nat Microbiol
Evolution of SARS-CoV-2 in the murine central nervous system drives viral diversification. [Abstract]2024 Sep;9(9):2383-2394. PMID: 39179693
Camostat mesylate purchased from MedChemExpress. Usage Cited in: Nat Microbiol. 2024 Sep;9(9):2383-2394. [Abstract]
TMPRSS2 inhibitor Camostat mesylate (0.01-100 μM) inhibited the WT pseudovirus approximately 3-fold better than the ΔFCS pseudovirus in VeroE6 cells overexpressing hACE2 and TMPRSS2 (VAT cells).
-
Nat Commun
Pathogenicity, virological features, and immune evasion of SARS-CoV-2 JN.1-derived variants including JN.1.7, KP.2, KP.3, and KP.3.1.1. [Abstract]2025 Dec 11;16(1):11002. PMID: 41381428 -
Nat Commun
Vesicle-associated membrane protein 5 is an intrinsic defense factor for embryonic stem cells against coronaviruses. [Abstract]2025 Jul 7;16(1):6241. PMID: 40624080 -
Nat Commun
Lineage-specific pathogenicity, immune evasion, and virological features of SARS-CoV-2 BA.2.86/JN.1 and EG.5.1/HK.3. [Abstract]2024 Oct 9;15(1):8728. PMID: 39379369 -
Nat Commun
Recreating the biological steps of viral infection on a cell-free bioelectronic platform to profile viral variants of concern. [Abstract]2024 Jul 3;15(1):5606. PMID: 38961055 -
Nat Commun
Paeniclostridium sordellii hemorrhagic toxin targets TMPRSS2 to induce colonic epithelial lesions. [Abstract]2022 Jul 26;13(1):4331. PMID: 35882856 -
Nat Commun
2022 Mar 17;13(1):1444. PMID: 35301316 -
Nat Chem Biol
2022 Sep;18(9):963-971. PMID: 35676539 -
Nucleic Acids Res
COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390 -
Sci Adv
2023 Jan 20;9(3):eadd3867. PMID: 36662861 -
Cell Discov
SARS-CoV-2 uses metabotropic glutamate receptor subtype 2 as an internalization factor to infect cells. [Abstract]2021 Dec 14;7(1):119. PMID: 34903715 -
EBioMedicine
The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5. [Abstract]2023 Sep:95:104753. PMID: 37579626 -
Cell Rep Med
2022 Sep 20;3(9):100743. PMID: 36084644 -
Sci China Life Sci
Receptor affinity-selective differential dynamics of membrane fusion initiation govern deltacoronavirus cross-species transmission. [Abstract]2025 Oct 24. PMID: 41144156 -
Proc Natl Acad Sci U S A
2022 Jan 25;119(4):e2117576119. PMID: 35022217 -
Emerg Microbes Infect
Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2. [Abstract]2022 Dec;11(1):2275-2287. PMID: 36039901 -
Sci Signal
The host protease KLK5 primes and activates spike proteins to promote human betacoronavirus replication and lung inflammation. [Abstract]2024 Aug 20;17(850):eadn3785. PMID: 39163389 -
Eur J Med Chem
System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2. [Abstract]2021 Nov 15:224:113683. PMID: 34273661 -
Cell Prolif
LL-37 Inhibits TMPRSS2-Mediated S2' Site Cleavage and SARS-CoV-2 Infection but Not Omicron Variants. [Abstract]2025 May 15:e70060. PMID: 40375579 -
Biochem Pharmacol
2023 Jul:213:115617. PMID: 37211174 -
Virulence
Bovine coronavirus enters PBIECs via membrane fusion and clathrin-, caveolin-mediated endocytosis, macropinocytosis. [Abstract]2026 Dec;17(1):2691344. PMID: 42334091 -
PLoS Pathog
UBXN7 facilitates SARS-CoV-2 replication via inhibiting the K48-linked ubiquitination of viral N protein. [Abstract]2025 Oct 14;21(10):e1013593. PMID: 41086194 -
Eur J Pharmacol
Mechanisms of acid-sensing ion channels inhibition by nafamostat, sepimostat and diminazene. [Abstract]2023 Jan 5:938:175394. PMID: 36403685 -
mBio
2022 Dec 20;13(6):e0256622. PMID: 36409074 -
Eur J Pharmacol
2022 Mar 15:919:174795. PMID: 35122868 -
Antiviral Res
Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2. [Abstract]2023 Jun:214:105606. PMID: 37076089 -
J Virol
Disruption of spike protein N-glycosylation induces its endoplasmic reticulum retention and attenuates SARS-CoV-2 infectivity. [Abstract]2026 Apr 21;100(4):e0027026. PMID: 41910405 -
J Virol
Bovine coronavirus enters HRT-18 cells via membrane fusion and clathrin-mediated endocytosis in a low pH-, dynamin-, cholesterol-, microtubule-, Rab7-, and Rab11-dependent manner. [Abstract]2025 Nov 18:e0127425. PMID: 41251346 -
J Virol
Cathepsin L and transmembrane serine protease 11E mediate trypsin-independent entry of porcine deltacoronavirus into Huh7 cells. [Abstract]2025 Aug 11:e0105525. PMID: 40787987 -
J Virol
Identification of Embryonic Chicken Proteases Activating Newcastle Disease Virus and Their Roles in the Pathogenicity of Virus Used as In Ovo Vaccine. [Abstract]2023 May 31;97(5):e0032423. PMID: 37042750 -
Viruses
Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19. [Abstract]2022 Feb 8;14(2):353. PMID: 35215943 -
Am J Physiol Renal Physiol
2024 Aug 1;327(2):F265-F276. PMID: 38867672 -
Biosaf Health
Establishment of a pseudovirus neutralization assay based on SARS-CoV-2 S protein incorporated into lentiviral particles. [Abstract]2022 Feb;4(1):38-44. PMID: 35005601 -
-
Res Sq
An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo. [Abstract]2024 Nov 21:rs.3.rs-5454588. PMID: 39606435 -
-
-
Res Sq
2023 Sep 11:rs.3.rs-3220157. PMID: 37790412 -
-
-
-
Solvent & Solubility
DMSO : 125 mg/mL (252.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : ≥ 50 mg/mL (101.11 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.21 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.21 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 12.5 mg/mL (25.28 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (537 KB)
- English - EN (537 KB)
- Français - FR (537 KB)
- Deutsch - DE (537 KB)
- Norwegian - NO (537 KB)
- Español - ES (537 KB)
- Swedish - SV (537 KB)
- Italian - IT (537 KB)
- Korean - KR (537 KB)
- Portuguese - PT (537 KB)
-
Handling Instructions (2659 KB)
References
[1]. Gibo J, et al. Camostat mesilate attenuates pancreatic fibrosis via inhibition of monocytes and pancreatic stellate cells activity. Lab Invest. 2005;85(1):75‐89. [Content Brief]
[2]. Uno Y. Camostat mesilate therapy for COVID-19 [published online ahead of print, 2020 Apr 29]. Intern Emerg Med. 2020;1‐2. [Content Brief]
[3]. Coote K, et al. Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J Pharmacol Exp Ther. 2009;329(2):764‐774. [Content Brief]
[4]. Zhou Y, Vedantham P, Lu K, et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015;116:76‐84. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.0222 mL | 10.1108 mL | 20.2216 mL | 50.5541 mL |
| 5 mM | 0.4044 mL | 2.0222 mL | 4.0443 mL | 10.1108 mL | |
| 10 mM | 0.2022 mL | 1.0111 mL | 2.0222 mL | 5.0554 mL | |
| 15 mM | 0.1348 mL | 0.6741 mL | 1.3481 mL | 3.3703 mL | |
| 20 mM | 0.1011 mL | 0.5055 mL | 1.0111 mL | 2.5277 mL | |
| 25 mM | 0.0809 mL | 0.4044 mL | 0.8089 mL | 2.0222 mL | |
| 30 mM | 0.0674 mL | 0.3370 mL | 0.6741 mL | 1.6851 mL | |
| 40 mM | 0.0506 mL | 0.2528 mL | 0.5055 mL | 1.2639 mL | |
| 50 mM | 0.0404 mL | 0.2022 mL | 0.4044 mL | 1.0111 mL | |
| 60 mM | 0.0337 mL | 0.1685 mL | 0.3370 mL | 0.8426 mL | |
| 80 mM | 0.0253 mL | 0.1264 mL | 0.2528 mL | 0.6319 mL | |
| 100 mM | 0.0202 mL | 0.1011 mL | 0.2022 mL | 0.5055 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Camostat mesylate Related Classifications
HY-13512 Related Classifications
Powered by Bioz